We conducted a targeted literature search to identify key studies examining the role of GLP-1 receptor agonists and SGLT2 inhibitors in patients with peripheral artery disease (PAD), including high-risk subgroups. This evidence concerns the gene GLP1R and peripheral arterial disease.